Organigram Global Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OGI research report →
Price Chart
About the company
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co.
- CEO
- James Yamanaka
- IPO
- 2019
- Employees
- 1,139
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on OGI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $82.21M
- P/E
- 1.33
- Fwd P/E
- 10.45
- PEG
- 0.00
- P/S
- 0.39
- P/B
- 0.24
- EV/EBITDA
- -5.03
- Div Yield
- 0.00%
- Gross Margin
- 2.22%
- Op Margin
- -31.84%
- Net Margin
- 28.02%
- ROE
- 21.99%
- ROIC
- -13.71%
Latest fiscal year · YoY change
- Revenue
- $186.09M+16.4%
- Gross Profit
- $6.83M-85.6%
- Op Income
- $-63,405,144
- Net Income
- $-17,776,962+60.9%
- EPS
- $-0.14+70.8%
- OCF Growth
- -296.0%
- FCF Growth
- -1580.8%
- 52W High
- $2.24
- 52W Low
- $0.58
- 50D MA
- $0.95
- 200D MA
- $1.15
- Beta
- 1.98
- RSI (14)
- 17
- Avg Volume
- 560.23K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Organigram posted record quarterly revenue and adjusted EBITDA, with Sanity Group driving a major shift toward a larger international business and improved margins.· August 11, 2026
- Net revenue hit a company record at $105.8 million, up 49% year over year, and adjusted EBITDA also reached a record $13.4 million.
- Adjusted gross margin improved to 37%, up 300 basis points year over year and 600 basis points sequentially.
- Sanity Group contributed EUR 24.5 million since April 15 and more than CAD 40 million of net revenue; international revenue was about 35% of consolidated revenue.
- Canadian share recovery began in vapes and infused pre-rolls, while flower, beverages, and concentrates remained strong.
- Management kept full-year guidance at revenue above $350 million, with adjusted gross margin and adjusted EBITDA expected to meaningfully exceed fiscal 2025 levels.
Q3 net revenue was $105.8 million, versus $70.8 million a year ago, up 49% year over year. Adjusted gross margin was 37%, up 300 basis points year over year and 600 basis points sequentially. Adjusted EBITDA was a record $13.4 million, versus $5.7 million in the prior year period. Net income was $105.5 million versus a loss of $6.3 million a year ago, driven mainly by $105.8 million of fair value gains. Cash provided by operating activities before working capital changes was $6.2 million, operating cash flow was an outflow of $4.3 million, and free cash flow was an outflow of $3.9 million. As of June 30, cash and cash equivalents were $11.7 million and total liquidity was $49.2 million. For fiscal 2026, management continues to expect revenue above $350 million, adjusted gross margin and adjusted EBITDA to meaningfully exceed fiscal 2025, and negative full-year free cash flow due to working capital needs; they still expect positive free cash flow in Q4.
James Yamanaka framed the quarter as a turning point, saying Organigram is now larger, more diversified, and increasingly international after nearly a full quarter of Sanity contribution. He highlighted recovery efforts in Canada, including a roughly 10% SKU reduction, stronger vape and infused pre-roll trends, and continued strength in flower, beverages, and concentrates. His tone was constructive and confident, emphasizing that the company is building a cash-generating global cannabis business and that the strategy is starting to show up in financial results.
Greg Guyatt emphasized that the quarter delivered the largest revenue in company history, improved adjusted gross margin, and record adjusted EBITDA. He pointed to Sanity as the main revenue and margin driver, while also noting better Canadian operations, lower G&A as a percentage of revenue at about 19%, and SG&A down to 31% of revenue from 34% a year ago. On cash flow, he said working capital investments, including inventory to address German demand and timing of sales, pressured operating cash flow and free cash flow, but underlying cash generation improved; cash and cash equivalents were $11.7 million and total liquidity was $49.2 million.
Analysts focused on Sanity integration, international growth, Germany margin dynamics, EU-GMP timing, and whether German supply issues were due to quality or regulatory pushback. Management said Sanity is performing in line with expectations, Germany has seen limited price compression so far, and demand remains strong, though EU-GMP flower supply is tight. They also said they expect minimal impact from Germany’s reimbursement changes and do not have a timeline for EU-GMP approval at Moncton, but believe certification would be meaningfully positive for margins.
The bull case from this call is that Organigram is showing record revenue and EBITDA while transitioning into a more diversified global platform with roughly 35% of revenue now international. Management sounded encouraged by early recovery in Canadian vapes and pre-rolls, continued flower leadership, and stable-to-strong Sanity demand with limited pricing pressure so far. They also guided to full-year revenue above $350 million and expect Q4 to be positive free cash flow.
The main risks are execution and working capital pressure: operating cash flow and free cash flow were negative this quarter, and management expects full-year free cash flow to remain negative because of integration and growth-related inventory needs. EU-GMP approval timing is still uncertain, and management described EU-GMP flower supply into Germany as tight, which could constrain growth. Canada also still faces competition and some softness in edibles, while U.S. activity is paused until regulatory clarity improves.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 68.8%
- Shares Outstanding
- 141.01M
- Float Shares
- 97.03M
of shares held by institutions
74 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tidal Investments LLC | 2.16M | ▼ 3.52K |
| Renaissance Technologies LLC | 1.41M | ▼ 33.80K |
| Advisorshares Investments LLC | 930.68K | ▲ 42.63K |
| Goldman Sachs Group Inc | 611.48K | ▲ 40.11K |
| Morgan Stanley | 308.11K | ▼ 56.08K |
| Baader Bank Aktiengesellschaft | 250.00K | ▼ 12.98K |
| Bank Of Montreal /Can/ | 236.79K | ▼ 1.65K |
| Formidable Asset Management, LLC | 208.80K | ▲ 48.49K |
| Two Sigma Advisers, LP | 184.67K | ▲ 106.48K |
| Susquehanna International Group, Llp | 153.60K | ▲ 44.15K |
| Old Mission Capital LLC | 147.14K | ▲ 147.14K |
| Ubs Group AG | 138.70K | ▼ 70.07K |
Held by 6 ETFs
Biggest fund positions in OGI by dollar value.
Our OGI coverage
Recent articles, reports, and earnings notes.
No research on OGI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OGI report →Organigram Provides NASDAQ Listing Update
businesswire.com · Nov 13
The Big Winner From the Aurora Cannabis-Organigram Deal: Curaleaf
fool.com · Nov 9
Organigram (NASDAQ: OGI) agrees to buy Aurora at a 93% premium, topping Curaleaf
defenseworld.net · Nov 6
Aurora Cannabis Stock: What Organigram's Buyout Means for Investors
zacks.com · Nov 4
Organigram to Acquire Aurora and Establish a Global Cannabis Leader
gurufocus.com · Nov 3
Organigram to Acquire Aurora and Establish a Global Cannabis Leader
businesswire.com · Nov 3
Organigram outbids Curaleaf with C$561M deal for Aurora Cannabis
proactiveinvestors.com · Nov 3
Sigma Lithium upsizes convertible bond offering to $125 million
proactiveinvestors.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.